The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cisplatin; Gefitinib

Criteria

Inclusion Criteria:

• Provision of written informed consent

• Patients with histologically proven primary SCCHN

• Aged 18 or over

Exclusion Criteria:

• Patients eligible for surgery with curative intent

• Other co-existing malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ

• Exclude UCNT